David Lenis

David Lenis

Auto-generated profile, based on publicly available information

David Lenis

Aetion, Inc New York New York USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2015 in Statistical Methods in Medical Research
Verified
Journal Article
Open access
PDF file
YWYenny Webb-Vargas
Yenny Webb-Vargas
KRKara E Rudolph
Kara E Rudolph
DLDavid Lenis
David Lenis
PMPeter Murakami
Peter Murakami
ESElizabeth A Stuart
Elizabeth A Stuart
Although covariate measurement error is likely the norm rather than the exception, methods for handling covariate measurement error in propensity score methods have not been widely investigated. We consider a multiple imputation-based approach that uses an external calibration sample with information on the true and mismeasured covariates, multiple imputation for external calibration, to correct for the measurement error, and investigate its performance using simulation studies. As expected, using the covariate measured with error leads to bias in the treatment effect estimate. In contrast, the multiple imputation for external calibration method can eliminate almost all the bias. We confirm that the outcome must be used in the imputation process to obtain good results, a finding related to the idea of congenial imputation and analysis in the broader multiple imputation literature. We illustrate the multiple imputation for external calibration approach using a motivating example estimating the effects of living in a disadvantaged neighborhood on mental health and substance use outcomes among adolescents. These results show that estimating the propensity score using covariates measured with error leads to biased estimates of treatment effects, but when a calibration data set is available, multiple imputation for external calibration can be used to help correct for such bias.

1 November 2024 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
NLNatalie S Levy
Natalie S Levy
PAPatrick J Arena
Patrick J Arena
TJThomas Jemielita
Thomas Jemielita
SMShahrul Mt-Isa
Shahrul Mt-Isa
SMShane McElwee
Shane McElwee
GHGleicy M Hair
Gleicy M Hair
Aim: To evaluate how transportability methods are currently used for real-world evidence (RWE) generation to inform good practices and support adoption and acceptance of these methods in the RWE context. Methods: We conducted a targeted literature review to identify studies that transported an effect estimate of the clinical effectiveness or safety of a biomedical exposure to a target real-world population. Records were identified from PubMed-indexed articles published any time before 25 July 2023 (inclusive). Two reviewers screened abstracts/titles and reviewed the full text of candidate studies to identify the final set of articles. Data on the therapeutic area, exposure(s), outcome(s), original and target populations and details of the transportability analysis (e.g., analytic method used, estimate transported, stated assumptions) were abstracted from each article. Results: Of 458 unique records identified, six were retained in the final review. Articles were published during 2021–2023, focused on the US/Canada context, and covered a range of therapeutic areas. Four studies transported an RCT effect estimate, while two transported effect estimates derived from real-world data. Almost all articles used weighting methods to transport estimates. Two studies discussed all transportability assumptions, and one evaluated the likelihood of meeting all assumptions and the impact of potential violations. Conclusion: The use of transportability methods for RWE generation is an emerging and promising area of research to address evidence gaps in settings with limited data and infrastructure. More transparent and rigorous reporting of methods, assumptions and limitations may increase the use and acceptability of transportability for producing robust evidence on treatment effectiveness and safety.

4 June 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
NLNatalie Levy
Natalie Levy
PSPaige Sheridan
Paige Sheridan
UCUlka Campbell
Ulka Campbell
DLDavid Lenis
David Lenis
IOInish O'DOherty
Inish O'DOherty
AMAnn Madsen
Ann Madsen
The Coalition to Advance Real‐World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative seeks to advance understanding of when real‐world data (RWD) can generate valid treatment effectiveness estimates by emulating completed oncology randomized controlled trials (RCTs). A prerequisite for meaningful RCT emulation insights is the identification and use of RWD with sufficient fitness to satisfy RCT‐specific data elements. We conducted a systematic, multi‐stage feasibility assessment of six commercially available US electronic health record‐based RWD sources across 23 candidate oncology RCTs. Each potential RCT‐RWD combination was first screened for availability of the RCT indication, outcomes, and sample size ≥ 1.5‐times enrollment for each trial arm. Combinations passing this screen underwent more detailed evaluation of RCT design elements including eligibility criteria, outcomes, and potential confounders. Each data element was rated with respect to availability, missingness, and validity. Final feasibility determination was informed by ratings of essential element capture and refined sample size estimates. Of 54 candidate RCT‐RWD combinations assessed, nine advanced to detailed feasibility assessment and three were selected for emulation protocol development. Fit‐for‐emulation constraints included complex eligibility criteria, biomarker requirements, performance status requirements, and outcome ascertainment. These findings highlight the importance of systematic feasibility evaluation before conducting emulations and may inform data selection for future RWD studies in oncology. Data fitness for oncology RCT emulation could be improved by linking high‐quality, oncology‐specific RWD sources to broader EHR and claims data sources or through customized data abstraction.